Artoss, Inc.

Artoss is proud to release the interim analysis of its ASTRO Post-Market Registry Study of NanoBone® Bone Graft in Spinal Fusion. At 12 months post-surgery, radiographic fusion was achieved in 90% of interbody fusion levels and 93% of posterior fusion levels. These fusion rates are consistent with published benchmarks for autograft. These data provide strong real-world evidence for the effectiveness of NanoBone in interbody and posterior spinal fusion across a diverse patient populate and procedural mix.